These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30626795)

  • 21. Initial treatment for patients with CML.
    Goldman JM
    Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dasatinib: A Review in Pediatric Chronic Myeloid Leukemia.
    McCafferty EH; Dhillon S; Deeks ED
    Paediatr Drugs; 2018 Dec; 20(6):593-600. PubMed ID: 30465234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
    Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
    Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
    Gambacorti-Passerini C; Antolini L; Mahon FX; Guilhot F; Deininger M; Fava C; Nagler A; Della Casa CM; Morra E; Abruzzese E; D'Emilio A; Stagno F; le Coutre P; Hurtado-Monroy R; Santini V; Martino B; Pane F; Piccin A; Giraldo P; Assouline S; Durosinmi MA; Leeksma O; Pogliani EM; Puttini M; Jang E; Reiffers J; Piazza R; Valsecchi MG; Kim DW
    J Natl Cancer Inst; 2011 Apr; 103(7):553-61. PubMed ID: 21422402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
    Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
    Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparison of simultaneous bone marrow cytogenetic and peripheral blood molecular responses in chronic myeloid leukemia].
    Lai Y; Qin Y; Huang X; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):104-8. PubMed ID: 24606648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.
    Eyüpoğlu D; Bozkurt S; Haznedaroğlu İ; Büyükaşık Y; Güven D
    Turk J Haematol; 2016 Mar; 33(1):60-5. PubMed ID: 27020722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surrogate end points for long-term outcomes in chronic myeloid leukemia.
    Akwaa F; Liesveld J
    Leuk Lymphoma; 2013 Oct; 54(10):2103-11. PubMed ID: 23383600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
    Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G;
    Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
    Tefferi A; Gotlib J; Pardanani A
    Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DRESS syndrome induced by imatinib.
    Kaur S; Singh S; Singh R; Singla P
    J Postgrad Med; 2021; 67(3):158-163. PubMed ID: 34427280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report.
    Li X; Cai S; Zhong Z; Wang H; Wang L; You Y; Zhang M
    Medicine (Baltimore); 2020 Feb; 99(9):e19256. PubMed ID: 32118733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy.
    Terao R; Nii M; Asai H; Nohara F; Okamoto T; Nagaya K; Azuma H
    J Oncol Pharm Pract; 2021 Apr; 27(3):756-760. PubMed ID: 32787559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
    Mizutani S; Kuroda J; Shimizu D; Horiike S; Taniwaki M
    Int J Hematol; 2010 Apr; 91(3):516-21. PubMed ID: 20146031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.
    Arai K; Yoshifuji K; Motomura Y; Sonokawa S; Suzuki S; Kumagai T
    Int J Hematol; 2019 Jun; 109(6):718-722. PubMed ID: 30788724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.